It is currently in Phase 3 clinical trials through Eli Lillys TRIUMPH program, with seven additional trial readouts expected in 2026
Key takeaways Well continue to see more innovation in this rapidly changing landscape
However, its suitability varies from person to person, based on individual health profiles and specific medical conditions
This common hurdle is a normal part of the weight loss journey, but you can prevail
For researchers transitioning to other compounds after completing tirzepatide protocols, the tirzepatide to retatrutide switching guide covers the transition considerations for moving to next-generation compounds
This approach would enable targeted intervention against the harmful metabolites without disrupting the commensal fungal community, offering a safer treatment strategy compared to broad-spectrum antifungal drugs